Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 5/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067744 | 0.88 | FGFR1 (0.48) | FGFR1SLC22A6BTN3A1 | |
| SCHEMBL25574764 | 0.82 | FGFR1 (0.56) | FGFR1SLC22A6BTN3A1 | |
| SCHEMBL14669082 | 0.80 | FGFR1 (0.80) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL14669220 | 0.80 | FGFR1 (0.80) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL14669196 | 0.80 | FGFR1 (0.80) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL16574525 | 0.79 | FGFR1 (0.68) | FGFR1SLC22A6EP300HPRT1 | |
| SCHEMBL14665357 | 0.78 | FGFR1 (0.67) | FGFR1SLC22A6EP300HPRT1 | |
| SCHEMBL20067738 | 0.77 | HPRT1 (0.55) | HPRT1 | |
| SCHEMBL14665385 | 0.77 | FGFR1 (0.66) | FGFR1SLC22A6EP300HPRT1 | |
| SCHEMBL24879340 | 0.73 | FGFR1 (0.56) | FGFR1SLC22A6EP300HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | KU LEUVEN RESEARCH & DEVELOPMENT (BE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105552-A1 | NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS | TYMP, MTAP, PNP | FGFR1 3291/4885SLC22A6 1268/4885FBP1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.